iTOL-101

A Potential Breakthrough for Type 1 Diabetes

iTOL-101 is a proof-of-concept study using our proprietary SA-FasL biotin-PEG microgel platform, iTOL-100, which acts to generate localized immune tolerance, allogeneic pancreatic islets implanted in the fat pad in the stomach, called the omentum. In a pre-clinical non-human primate study, transplanted pancreatic islets have been shown to act similar to native pancreatic islets, secreting insulin in response to sugar intake. Most importantly, study animals did not require long-term immunosuppression therapy to maintain pancreatic islet viability and function.

Program Highlights:

Compelling Results Demonstrated in NHP Study Published in Science Advances

Long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression.

How iTOL-100 is Designed to Work

Even with Insulin Treatment, There Remains a Significant Unmet Need in Type 1 Diabetes

Type 1 Diabetes is a chronic condition in which the pancreas produces little or no insulin. People with brittle diabetes frequently experience large swings in blood sugar that can quickly move from too high to too low or vice versa. Severely low blood sugar, called hypoglycemia, can cause sudden and unexpected seizures, coma, heart attacks, and even death.

70K – 100K

very severe uncontrolled
type 1 diabetes; “brittle”²